BIOTAGE AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 165.5 SEK | +0.49% |
|
+4.42% | +23.78% |
| 25/04 | Transcript : Biotage AB, Q1 2024 Earnings Call, Apr 25, 2024 | |
| 25/04 | Biotage AB Approves a Dividend, Payable on May 3, 2024 | CI |
| Sales 2024 * | 2.17B 199M 16.57B | Sales 2025 * | 2.39B 218M 18.19B | Capitalization | 13.24B 1.21B 101B |
|---|---|---|---|---|---|
| Net income 2024 * | 277M 25.32M 2.11B | Net income 2025 * | 357M 32.63M 2.72B | EV / Sales 2024 * | 5.87 x |
| Net cash position 2024 * | 473M 43.24M 3.6B | Net cash position 2025 * | 780M 71.25M 5.94B | EV / Sales 2025 * | 5.22 x |
| P/E ratio 2024 * |
47.9
x | P/E ratio 2025 * |
37.2
x | Employees | 669 |
| Yield 2024 * |
1.12% | Yield 2025 * |
1.27% | Free-Float | 99.55% |
More Fundamentals
* Assessed data
More news
Latest transcript on Biotage AB
More press releases
More news
| 1 day | +0.49% | ||
| 1 week | +4.42% | ||
| Current month | -9.02% | ||
| 1 month | -9.02% | ||
| 3 months | +11.98% | ||
| 6 months | +50.87% | ||
| Current year | +23.78% |
1 week
156.20
167.10
1 month
156.20183.30
Current year
122.20187.10
1 year
83.05187.10
3 years
83.05295.60
5 years
78.05295.60
10 years
9.80295.60
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 72 | 09/06/09 | |
Andrew Kellett
DFI | Director of Finance/CFO | 56 | 25/23/25 |
| Chief Tech/Sci/R&D Officer | 54 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 72 | 09/06/09 | |
Åsa Hedin
BRD | Director/Board Member | 62 | 01/19/01 |
Kieran Murphy
CHM | Chairman | 61 | 04/01 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 773 M€ | -.--% | - | |
| 0.00% | 10 M€ | -3.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 165.5 | +0.49% | 296,758 |
| 25/24/25 | 164.7 | +2.49% | 301,585 |
| 24/24/24 | 160.7 | -1.35% | 84,575 |
| 23/24/23 | 162.9 | +1.81% | 161,878 |
| 22/24/22 | 160 | +0.95% | 311,421 |
Delayed Quote Nasdaq Stockholm, April 26, 2024 at 08:59 pm IST
More quotes
Biotage AB is a Sweden-based company that develops and sells systems, consumables and services in the field of life sciences. Its customers include pharmaceutical and biotechnology companies, companies within the food industry and academic institutions. The Company offers systems and services within three areas: analytical chemistry, organic chemistry and industrial resins. Biotageâs offering within analytical chemistry consists of consumables with related applications to extract selected substances from various types of samples. The Companyâs offering within organic chemistry includes products for pharmaceutical development based on both small molecules and peptides and its offering within industrial resins is composed of polymer-based resins and research services that lead to the development and manufacture of polymer-based materials. As of December 31, 2013, the Company operated 12 wholly owned subsidiaries worldwide.
Calendar
16/07/2024
- Q2 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
165.5
SEK
Average target price
186.7
SEK
Spread / Average Target
+12.79%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +23.78% | 1.21B | |
| -12.91% | 19.08B | |
| -46.21% | 2.65B | |
| +18.15% | 1.87B | |
| -3.12% | 1.61B | |
| -10.69% | 1.02B | |
| -20.89% | 905M | |
| -7.14% | 716M | |
| -18.10% | 682M | |
| +4.01% | 480M |
- Stock Market
- Equities
- BIOT Stock
